Market Overview

Hepatitis C Stocks Move After Idenix Rockets Up 235%

Share:

Hepatitis C stocks are heating up Monday morning after Merck (NYSE: MRK) announced a 239 percent premium on Idenix Pharmaceuticals (NASDAQ: IDIX). Shares of Idenix are trading up 235 percent in the pre-market, just $0.24 away from Merck’s offer.

Merck shares were trading down 0.67 percent to $57.46. This weakness indicates some shareholders may think Merck is overpaying for Idenix because the deal will not dilute Merck shares.

Related: ASCO meeting Day 4: Risks And Rewards Of Immunotherapy

The extremity of the offer completely changes hepatitis C industry valuation. New valuations are reflected in Monday mornings trading. Achillion Pharmaceuticals (NASDAQ: ACHN) shares are up ~35 percent and Enanta Pharmaceuticals (NASDAQ: ENTA) are up ~4.03 percent.

The massive premium Merck is paying for Idenix indicates that commercial viability is more likely than Wall Street had anticipated.

Subsequently, shares of competitors are experiencing some weakness in Monday morning's trading.

Gilead Sciences (NASDAQ: GILD) shares are down 0.83 percent. AbbVie (NYSE: ABBV) shares are down 0.91 percent; AbbVie started a Phase III study of its hepatitis C drug at the end of 2012.

Posted-In: Hepatitis CM&A News Trading Ideas

 

Related Articles (ACHN + ABBV)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Morgan Stanley Initiates Coverage On Zendesk As Emerging Market Leader

McDonald's Reports May Same-Store Sales